We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

104 hedge funds and large institutions have $147M invested in Sciclone Pharmaceuticals Inc in 2013 Q2 according to their latest regulatory filings, with 104 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less call options, than puts

Call options by funds: $707K | Put options by funds: $806K

Holders
104
Holders Change
+104
Holders Change %
–
% of All Funds
3.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
104
Increased
–
Reduced
–
Closed
–
Calls
$707K
Puts
$806K
Net Calls
-$99K
Net Calls Change
-$99K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
76
Boston Advisors
Massachusetts
$113K +$108K +22,800 New
WCM
77
Wedge Capital Management
North Carolina
$105K +$101K +21,125 New
MC
78
Menta Capital
California
$103K +$98.8K +20,752 New
Citigroup
79
Citigroup
New York
$102K +$98.3K +20,667 New
RFC
80
Russell Frank Company
Washington
$94K +$90.3K +18,966 New
BNP Paribas Financial Markets
81
BNP Paribas Financial Markets
France
$88.8K +$85.2K +17,894 New
B
82
Barings
North Carolina
$88K +$84.2K +17,700 New
Cambridge Investment Research Advisors
83
Cambridge Investment Research Advisors
Iowa
$84K +$80.3K +16,879 New
DIA
84
Denver Investment Advisors
Colorado
$73K +$69.6K +14,627 New
QI
85
QS Investors
New York
$72K +$69K +14,500 New
BJ
86
BlackRock Japan
Japan
$66K +$63.7K +13,382 New
EMG
87
Ellington Management Group
Connecticut
$65K +$62.3K +13,100 New
ZCM
88
Zebra Capital Management
Connecticut
$65K +$62.5K +13,139 New
RCM
89
Rotella Capital Management
Washington
$61K +$58.3K +12,255 New
Citadel Advisors
90
Citadel Advisors
Florida
$58K +$55.2K +11,594 New
RA
91
Royce & Associates
New York
$58K +$55.7K +11,700 New
Barclays
92
Barclays
United Kingdom
$53K +$50.6K +10,624 New
EWM
93
Evercore Wealth Management
New York
$40K +$38.1K +8,000 New
CBOA
94
Commonwealth Bank of Australia
Australia
$20K +$18.8K +3,941 New
Teacher Retirement System of Texas
95
Teacher Retirement System of Texas
Texas
$16K +$15.2K +3,198 New
PNC Financial Services Group
96
PNC Financial Services Group
Pennsylvania
$14K +$13.1K +2,743 New
BlackRock
97
BlackRock
New York
$11K +$10.6K +2,230 New
BG
98
BlackRock Group
United Kingdom
$8K +$8.02K +1,686 New
Royal Bank of Canada
99
Royal Bank of Canada
Ontario, Canada
$6K +$6.12K +1,286 New
Creative Planning
100
Creative Planning
Kansas
$5K +$4.76K +1,000 New
1 2 3
4
5

SCLN Hedge Fund Activity: Q2 2013 in Review

104 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2013, worth a combined $147M.

Buyers outnumbered sellers: 104 funds opened new SCLN positions and 0 closed out — a net gain of 104 holders — while 0 added to existing stakes and 0 trimmed.

  • 104 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $147M of Sciclone Pharmaceuticals Inc stock for Q2 2013.
  • 104 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2013 and 0 closed out, a net change of +104 holders.

Based on aggregated 13F filings for Q2 2013.